Cancelled by the investigator Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)

INTERVENTION: Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document "Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT‐PCR and negative result rate of the novel coronavirus disease nucleic acid; SECONDARY OUTCOME: Comparison of TCM symptom score (degree of fever, cough, sputum, chest tightness, shortness of breath, anorexia, abdominal distension, the tongue proper and the tongue coating, pulse condition);comparison of changes in SpO2, oxygen saturation, lymphocyte count;Clinical recovery time: the body temperature returned to normal and lasting for more than 3 days, the respiratory symptoms improved significantly, and the test result was negative for two consecutive times (ended at the time of the first negative result);Comparison of conversion rates of severe (severe or critical) subjects in each group;Comparison of changes in inflammation indicators (white blood cell count, C‐reactive protein, ESR, procalcitonin) before and after treatment; INCLUSION CRITERIA: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease; 2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung; 3) Inpatients aged 18 to 75 years male or female; 4) Volunteer to receive treatment under their own scheme and sign informed consent.